|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3800 AUD | 0.00% |
|
+4.11% | -41.54% |
| 30/07 | Recce Pharmaceuticals in Position to Benefit from US ASPR Medical Countermeasures Strategy | MT |
| 21/07 | Recce Pharmaceuticals Reports Higher Cash Balance in June Quarter | MT |
| Market Cap | 11Cr 7.96Cr 6.92Cr 6.46Cr 5.93Cr 11Cr 759.05Cr 76Cr 30Cr 378.52Cr 30Cr 29Cr 1.25TCr | P/E 2026 * |
-6.23x | P/E 2027 * | -4.47x |
|---|---|---|---|---|---|
| Enterprise Value | 12Cr 8.33Cr 7.24Cr 6.76Cr 6.2Cr 12Cr 793.97Cr 80Cr 31Cr 395.94Cr 31Cr 31Cr 1.31TCr | EV / Sales 2026 * |
15.3x | EV / Sales 2027 * | 11.1x |
| Free-Float |
60.61% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 week | +4.11% | ||
| Current month | +2.70% | ||
| 3 months | -20.00% | ||
| 6 months | -33.91% | ||
| Current year | -41.54% |
| 1 week | 0.36 |  | 0.38 |
| 1 month | 0.35 | | 0.39 |
| Current year | 0.35 | | 0.73 |
| 1 year | 0.35 | | 0.73 |
| 3 years | 0.28 | | 0.76 |
| 5 years | 0.28 | | 1.38 |
| 10 years | 0.13 | | 1.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
James Graham
CEO | Chief Executive Officer | - | 28/08/2020 |
Justin Reynolds
DFI | Director of Finance/CFO | - | - |
Michele Dilizia
CTO | Chief Tech/Sci/R&D Officer | - | 30/09/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Michele Dilizia
BRD | Director/Board Member | - | 01/10/2012 |
James Graham
BRD | Director/Board Member | - | 01/05/2012 |
| Director/Board Member | - | 01/09/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 24/02/26 | Expiration | Chief Executive Officer | 22,50,000 | 0.7781% | ||
| 14/10/25 | Expiration | Chief Executive Officer | 7,45,962 | 0.3217% | ||
| 21/11/24 | Buy | Director | 10,00,000 | 0.4313% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | +4.11% | +1.33% | -39.20% | 7.96Cr | |
| -2.39% | -6.36% | +47.10% | +149.66% | 1LCr | |
| -0.76% | -4.34% | +52.04% | +49.09% | 61TCr | |
| -2.33% | -4.60% | +25.55% | +64.44% | 43TCr | |
| +0.68% | -1.14% | +38.47% | +33.36% | 35TCr | |
| -1.66% | -3.13% | +32.18% | +39.79% | 29TCr | |
| -8.96% | -10.77% | +3.57% | +5.50% | 24TCr | |
| -1.37% | -7.41% | -2.10% | -43.67% | 21TCr | |
| -1.63% | +0.69% | +27.62% | +64.23% | 20TCr | |
| +0.72% | +0.48% | +15.88% | +73.64% | 16TCr | |
| Average | -1.38% | -3.36% | +24.16% | +39.68% | 35.01TCr | |
| Weighted average by Cap. | -0.93% | -4.34% | +34.73% | +70.96% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 77.79L 54.44L 47.31L 44.17L 40.55L 76.46L 52Cr 5.21Cr 2.04Cr 26Cr 2.04Cr 2Cr 85Cr | 1.25Cr 87.44L 76L 70.95L 65.13L 1.23Cr 83Cr 8.37Cr 3.28Cr 42Cr 3.28Cr 3.21Cr 137.09Cr |
| Net income | -1.83Cr -1.28Cr -1.11Cr -1.04Cr -95.35L -1.8Cr -122.01Cr -12Cr -4.8Cr -61Cr -4.81Cr -4.7Cr -200.69Cr | -2.51Cr -1.76Cr -1.53Cr -1.43Cr -1.31Cr -2.47Cr -167.41Cr -17Cr -6.58Cr -83Cr -6.6Cr -6.45Cr -275.36Cr |
| Net Debt | 52.35L 36.63L 31.84L 29.72L 27.29L 51.45L 35Cr 3.5Cr 1.37Cr 17Cr 1.38Cr 1.35Cr 57Cr | 2.5Cr 1.75Cr 1.52Cr 1.42Cr 1.3Cr 2.45Cr 166.51Cr 17Cr 6.55Cr 83Cr 6.56Cr 6.42Cr 273.88Cr |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/26/04 | A$0.3800 | 0.00% | 2,449 |
| 03/26/03 | A$0.3800 | +2.70% | 1,20,803 |
| 31/26/31 | A$0.3700 | -1.33% | 29,912 |
| 30/26/30 | A$0.3750 | +2.74% | 55,543 |
| 29/26/29 | A$0.3650 | 0.00% | 35,714 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- RCE Stock
Select your edition
All financial news and data tailored to specific country editions
